Ondine Biopharma Receives CE Mark Approval for PERIOWAVE
Advertisement
Ondine Biopharma Corporation announced CE Mark approval for its proprietary Periowave(TM) Photodynamic disinfection (PDD) System for the treatment of periodontal diseases. This regulatory milestone clears the way for Ondine to begin preparations for marketing its laser-based antimicrobial system throughout the EU as well as selected countries throughout the world.
"CE Mark approval permits us to expand our market reach beyond Canada, where Periowave(TM) is currently being sold," said Carolyn Cross, President and CEO of Ondine Biopharma. "The CE Mark also indicates that we have met the essential health, safety and environmental protection requirements detailed in the European Directives covering medical devices." Periowave(TM) is a Photodynamic Disinfection system that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodynamic Disinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Biomedica PLC, University College London.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Stem cell transplantation: Chance of survival increases with number of procedures - IQWiG examines evidence for minimum volumes

Study reveals the structure of the 2nd human cannabinoid receptor
Evogene Participates In Israeli Agbio Consortium - BIOTOV MAGNET Consortium to focus on improved Nutritional Qualities for Fruits and Vegetable

Revealing the secrets of cell competition - Which features distinguish “winner” from “loser” cells
BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodies

Avoiding animal testing with vegan antibodies - Spin-off project "Ymolution" launched

A matter of timing - To bloom or not to bloom? Max Planck researchers discover how flowering time is affected by temperature

Peanut Allergy Prevention: Researchers Uncover Groundbreaking Solution
List_of_subjects_in_Gray's_Anatomy:_VI._The_Arteries
